Rezolute, Inc. (RZLT) — 10-Q Filings

10-Q Filings (6)

• Rezolute's Q1 Loss Widens Amid Increased R&D, Cash Drains — Nov 6, 2025 Risk: high
  Rezolute, Inc. (RZLT) reported a net loss of $18.15 million for the three months ended September 30, 2025, an increase from the $15.38 million net loss in the s
• Rezolute, Inc. Files Q3 2025 10-Q — May 13, 2025 Risk: medium
  Rezolute, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as AntriaBio, Inc., is in the pharmaceutical preparations indust
• Rezolute, Inc. Files 10-Q for Q2 2025 — Feb 12, 2025 Risk: medium
  Rezolute, Inc. filed its 10-Q for the period ending December 31, 2024. The company, formerly known as AntriaBio, Inc., is in the pharmaceutical preparations sec
• Rezolute, Inc. Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Rezolute, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as AntriaBio, Inc., is incorporated in Nevada and operates i
• Rezolute, Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: medium
  Rezolute, Inc. (RZLT) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Rezolute, Inc. reported revenue of $36.827 million for the nine months ended
• Rezolute, Inc. Files 10-Q for Period Ending December 31, 2023 — Feb 13, 2024 Risk:
  Rezolute, Inc. (RZLT) filed a Quarterly Report (10-Q) with the SEC on February 13, 2024. Rezolute, Inc. filed a 10-Q report for the period ending December 31, 2

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX